CEL-SCI Corporation (CVM)
| Market Cap | 11.57M -43.5% |
| Revenue (ttm) | n/a |
| Net Income | -23.81M |
| EPS | -4.32 |
| Shares Out | 8.09M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,115,445 |
| Open | 1.280 |
| Previous Close | 1.300 |
| Day's Range | 1.280 - 1.560 |
| 52-Week Range | 0.890 - 13.477 |
| Beta | 0.71 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 15, 2026 |
About CVM
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company’s lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections,... [Read more]
Financial Performance
Financial StatementsNews
CEL-SCI Announces Closing of Public Offering
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI announces closing of public offering.
CEL-SCI 6M share Secondary priced at $1.20
ThinkEquity acted as sole book running manager for the offering.
CEL-SCI Corporation Announces Pricing of Public Offering
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Corporation Announces Pricing of Public Offering.
CEL-SCI enters strategic agreement with Amarox over Multikine distribution
CEL-SCI (CVM) announced it has signed a strategic partnership, distribution, and revenue sharing agreement with Amarox for regulatory affairs, marketing and potential commercialization of Multikine in...
CEL-SCI Enters Strategic Agreement with Amarox for the Registration, Commercialization, and Distribution of Multikine in Saudi Arabia
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Enters Strategic Agreement with Amarox for the Registration, Commercialization, and Distribution of Multikine in Saudi Arabia.
CEL-SCI files to sell 3.44M shares of common stock
ThinkEquity is acting as the exclusive placement agent in connection with this offering.
CEL-SCI Reports Fiscal First Quarter 2026 Results
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI reported financial results for three months ended December 31, 2025, as well as key recent clinical and corporate developments.
CEL-SCI Reports Fiscal 2025 Results
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Corporation reports financial results for the fiscal year ended September 30, 2025, as well as key clinical and corporate developments.
CEL-SCI files to sell 375,000 shares of common stock for holders
16:32 EST CEL-SCI (CVM) files to sell 375,000 shares of common stock for holders
CEL-SCI Presentation at LD Micro "Main Event" Available on Tuesday, October 21, 2025
Vienna, Virginia--(Newsfile Corp. - October 20, 2025) - CEL-SCI Corporation (NYSE American: CVM), a clinical stage cancer immunotherapy company, previously announced that Geert Kersten, Chief Executiv...
CEL-SCI Corporation to Present at LD Micro "Main Event" Investor Conference
Vienna, Virginia--(Newsfile Corp. - October 10, 2025) - CEL-SCI Corporation (NYSE American: CVM), a clinical stage cancer immunotherapy company, today announced that Geert Kersten, Chief Executive Off...
CEL-SCI Announces Closing of $10 Million Public Offering
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI announces closing of $10 million public offering.
CEL-SCI 1.11M share Spot Secondary priced at $9.00
The deal priced below last closing price of $13.04. ThinkEquity is acting as sole book running manager for the offering.
CEL-SCI Announces Pricing of $10 Million Public Offering
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI announces pricing of $10 million public offering.
CEL-SCI announces common stock offering, no amount given
CEL-SCI (CVM) announced that it intends to offer to sell shares of its common stock in a best-efforts public offering. All of the shares of common stock are being offered…
CEL-SCI Announces Proposed Public Offering
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a clinical stage cancer immunotherapy company, today announced that it intends to offer to sell sha...
CEL-SCI reports Q3 EPS ($1.36) vs. ($4.18) last year
“Commercial and regulatory momentum for Multikine is accelerating due to three driving factors-our partnership negotiations in Saudi Arabia, the increasing interest in CEL-SCI (CVM) from investors in ...
CEL-SCI Reports Fiscal Third Quarter 2025 Financial Results
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI reports fiscal third quarter 2025 financial results.
CEL-SCI files for breakthrough designation for Multikine in Saudi Arabia
CEL-SCI (CVM) announced that a Breakthrough Medicine Designation application has been filed with the Saudi Food and Drug Authority for Multikine in Saudi Arabia. The application was submitted by a…
CEL-SCI's Multikine Head and Neck Cancer Immunotherapy Breakthrough Medicine Designation Filed in Saudi Arabia: Allows for Patient Access and Reimbursement/Sale Upon Granting of the Designation Which Takes Approximately 60 Days Based on SFDA Timeline
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI's Multikine Head and Neck Cancer Immunotherapy Breakthrough Medicine Designation Filed in Saudi Arabia.
CEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American Rules
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI announces closing of $5.7 million offering priced at-the-market under NYSE American rules.
CEL-SCI announces pricing of $5.7M at-the-market common stock offering
CEL-SCI (CVM) Corporation announced the pricing of a best-efforts offering of 1.5M shares of its common stock. Each share of common stock is being sold at an offering price of…
CEL-SCI Announces Pricing of $5.7 Million Offering Priced At-the-Market Under NYSE American Rules
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI announces pricing of $5.7 million offering priced at-the-market under NYSE American rules.
CEL-SCI teams with Saudi Arabia pharmaceutical, healthcare company for Multikine
CEL-SCI (CVM) announced it has reached an agreement with one of Saudi Arabia’s pharmaceutical and healthcare companies for a partnership that spans regulatory and commercial activities for Multikine i...
CEL-SCI to Sign Partnership Agreement With Leading Saudi Arabian Pharma Company for Multikine in the Treatment of Head & Neck Cancer
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI to sign partnership agreement with leading Saudi Arabian pharma company for Multikine in the treatment of head & neck cancer.